ICICI Prudential Asset Management Co Ltd Buys 3,466 Shares of Gilead Sciences, Inc. $GILD

ICICI Prudential Asset Management Co Ltd raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,055 shares of the biopharmaceutical company’s stock after purchasing an additional 3,466 shares during the period. ICICI Prudential Asset Management Co Ltd’s holdings in Gilead Sciences were worth $2,115,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of GILD. Clear Creek Financial Management LLC grew its stake in shares of Gilead Sciences by 1.9% during the 3rd quarter. Clear Creek Financial Management LLC now owns 14,901 shares of the biopharmaceutical company’s stock worth $1,654,000 after acquiring an additional 278 shares during the period. VeraBank N.A. lifted its holdings in Gilead Sciences by 4.5% during the third quarter. VeraBank N.A. now owns 3,744 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 161 shares during the last quarter. Avestar Capital LLC boosted its position in Gilead Sciences by 5.7% during the third quarter. Avestar Capital LLC now owns 19,154 shares of the biopharmaceutical company’s stock worth $2,126,000 after purchasing an additional 1,040 shares during the period. NewEdge Wealth LLC increased its stake in shares of Gilead Sciences by 2.9% in the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock worth $75,962,000 after purchasing an additional 17,284 shares in the last quarter. Finally, MJP Associates Inc. ADV raised its position in shares of Gilead Sciences by 14.9% in the third quarter. MJP Associates Inc. ADV now owns 2,129 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 276 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 319,891 shares of company stock valued at $45,091,556 over the last quarter. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on GILD shares. Scotiabank lifted their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. BMO Capital Markets boosted their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. Rothschild & Co Redburn increased their price objective on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday. Wolfe Research lifted their target price on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Twenty-three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $154.21.

Gilead Sciences Stock Down 1.1%

GILD stock opened at $151.12 on Friday. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The stock has a market cap of $187.49 billion, a price-to-earnings ratio of 22.32, a price-to-earnings-growth ratio of 2.03 and a beta of 0.36. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company’s 50 day moving average is $132.85 and its 200 day moving average is $123.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.